Crossmark

Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Crossref DOI link: https://doi.org/10.1186/s13613-022-01059-9

Published Online: 2022-09-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chabert, Paul https://orcid.org/0000-0001-8697-6415
Provoost, Judith

Cohen, Sabine

Dupieux-Chabert, Céline

Bitker, Laurent

Ferry, Tristan

Goutelle, Sylvain

Richard, Jean-Christophe
License Information

Text and Data Mining valid from 2022-09-30

Version of Record valid from 2022-09-30
More Information

Article History

Received: 28 May 2022

Accepted: 1 September 2022

First Online: 30 September 2022

Declarations

:

: Subjects received an information sheet mentioning their participation to the study unless refusal, and consent was waived according to French legislation. The study was approved by the Scientific and Ethical Committee of Hospices Civils de Lyon on 7 December 2021 (n 21_284).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below